‘Increased survival rates’ for bladder cancer patients given immunotherapy drug
Experts said Durvalumab could be a ‘game changer’.
Related Articles
ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update
The availability and affordability of safe, effective cancer therapies are core requirements for effective cancer control. Global disparities exist in access, however, yielding unequal cancer…
World Cancer Day 2025: International Journal of Cancer
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
Cuts to Medicare Physician Reimbursement Take Effect After Congress Fails to Pass Legislation
“For the fifth consecutive year, Congress has adjourned and allowed Medicare cuts,” said Bruce A. Scott, MD, president of the AMA.
Bleeding eye disease kills eight after outbreak in new country
WHO sounds alarm after deadly Marburg virus kills 8 people in key east African transport hub
Shipp’s Passion Leads to Transformative Research, Innovations in Lymphoma
After answering her calling for hematology oncology, Margaret A. Shipp, MD, shook up lymphoma research by exploiting the PD-1 pathway to evade immune detection and…
Tarlatamab Earns UK Approval for Previously Treated ES-SCLC
Tarlatamab was granted conditional marketing authorization in the United Kingdom for previously treated extensive-stage small cell lung cancer.
Treatment of Pleural Mesothelioma: ASCO Guideline Update
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the…
LOTIS-5 Trial of Lonca-R Completes Enrollment in R/R DLBCL
Enrollment in the LOTIS-5 trial of loncastuximab tesirine-lpyl with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma has been completed.
Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC
Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.
Understanding the experience of Latinas in medical education: A qualitative study
Despite improvements in recruitment of Latina medical students, the percentage of Latina physicians has remained stagnant, suggesting unique barriers to retention and career advancement. This…
